News and features

If watching the stunning displays of athleticism in the Olympics inspired you to become more physically active, then why not consider becoming part of Team ICR? You could take part in one or more of our exciting sporting challenges — either here in the UK or around the world

Testing for the activity of two genes could pick out women who are at increased risk of dying from their breast cancers, suggests a new study of almost 2,000 patients.

Scientists have identified how an inherited genetic variant, associated with an increased risk of developing the most common type of leukaemia, helps cancer cells survive.

Combining radiotherapy with a virus that targets cancer cells kicks both treatments into overdrive to treat the deadliest form of skin cancer, a new study shows.

Genetic testing of patients with a rare form of cancer that can affect children and young adults can pick out genetic errors hidden in their family tree which increase the risk of a wide variety of cancer types.

Despite major breakthroughs in creating innovative cancer drugs, there is still an urgent need to explore more treatment options. Liz Burtally finds out how researchers are now looking outside the historical, well-trodden cancer pathways usually targeted by cancer therapeutics.

World-leading cancer researchers have revealed plans to create a new generation of ‘anti-evolution’ therapies, designed to combat cancer’s lethal ability to adapt and evade treatment.

The Institute of Cancer Research, London, has named Professor Johann de Bono as Regius Professor of Cancer Research.

Professor Paul Workman, Chief Executive of The Institute of Cancer Research, London, and Professor Jon Pines, Head of Cancer Biology, will be admitted as Fellows to the Royal Society on Friday 15 July 2016 — the greatest honour in UK science.

Day-to-day psychological stress and adverse life events are unlikely to increase a woman’s risk of developing breast cancer, according to a major new prospective study.

A new streamlined approach to genetic testing for women with ovarian cancer provides testing rapidly and affordably, allowing many more patients to benefit from personalised cancer management and their relatives to benefit from cancer prevention strategies.

A new test could predict the risk of a woman’s breast cancer spreading within 10 years of diagnosis more accurately than the current NICE-approved test, Oncotype DX, scientists have found.